Marksans Pharma has announced that its wholly-owned subsidiary Relonchem has received Marketing Authorisation for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution from UK Medicines and Healthcare Products Regulatory Agency (MHRA).

Headquartered in Mumbai, Marksans Pharma is engaged in research, manufacturing and marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and the UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA.

“The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally,” said the company in a statement.